No Data
No Data
Express News | Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Press Release: Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Cassava Sciences Updates on Phase 3 Alzheimer's Trial Ahead of Key Readout
Cassava Sciences' Simufilam 100 Mg For Mild-To-Moderate Alzheimer's Disease (RETHINK-ALZ) Posted On ClinicalTrials Website On November 15, 2024
Cassava Sciences Analyst Ratings
H.C. Wainwright Maintains Cassava Sciences(SAVA.US) With Buy Rating, Maintains Target Price $116
No Data
No Data